sGC Stimulators and Activators for Digital Ulcer Healing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for systemic sclerosis and associated digital ulcers are limited in efficacy and safety, with no approved treatment for healing digital ulcers, and existing therapies for systemic sclerosis do not effectively address the underlying fibrosis and vasculopathies that lead to these ulcers.
Innovation Solution
The use of sGC stimulators and activators, alone or in combination with PDE5 inhibitors, to target skin fibrosis and vasculopathies, promoting peripheral vasodilation and potentially accelerating wound healing by reducing collagen synthesis and enhancing blood flow.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current immunosuppressant and antifibrotic therapies are used for systemic sclerosis, then immune system suppression is achieved, but tolerability is limited and side effects are considerable
Solution Approach 1:
The patent changes the therapeutic parameter from immunosuppression to direct antifibrotic action on skin fibroblasts. sGC stimulators and activators modify the cellular environment by increasing cGMP levels, which directly counteracts fibrotic processes without suppressing the immune system, thereby achieving treatment efficacy while avoiding immunosuppressant side effects
Solution Approach 2:
The patent introduces sGC stimulators and activators as intermediary substances that mediate between the pathological fibrotic process and therapeutic intervention. These compounds act as mediators by binding to soluble guanylate cyclase and modulating cGMP production, which then regulates fibroblast behavior and extracellular matrix deposition, providing a targeted therapeutic mechanism that bypasses immune system involvement
2Speed
If vasoactive drugs are used for digital ulcer treatment, then vasodilation is achieved, but wound healing is impaired due to reduced collagen synthesis
Solution Approach 1:
The patent applies local quality by targeting specific cell types (skin fibroblasts) with selective antifibrotic effects. sGC stimulators and activators exhibit cell-type specificity, affecting fibroblast function and collagen production locally while maintaining normal vasodilation through the nitric oxide-cGMP pathway, thereby resolving the contradiction between vascular improvement and wound healing
Solution Approach 2:
The patent uses partial action by selectively modulating cGMP signaling in fibroblasts without completely blocking vasodilation. The therapeutic window is optimized to achieve sufficient antifibrotic effect while maintaining adequate blood flow, using controlled dosing regimens that provide partial vasodilation (sufficient for ulcer healing) while exerting strong antifibrotic effects on collagen synthesis
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The sGC stimulators and activators significantly accelerate wound healing in animal models of systemic sclerosis, normalizing healing times to those of healthy controls, suggesting they can prevent and heal digital ulcers by addressing both fibrosis and vasculopathies.
Implementation Method 1
The cyclic nucleotides, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), were discovered decades ago and represent one of the most important second messenger pathway within cells. It is well established that the regulation of intra-cellular cGMP pools have substantial impact on physiology, and pathophysiology
Implementation Method 2
PDE5 inhibitors are the gold-standard for the treatment of erectile dysfunction (ED) but it was shown that PDE5 inhibitors could be useful for the treatment of symptomatic BPH
Implementation Method 3
The antifibrotic effects of Vardenafil, sGC stimulators and sGC activators is not understood yet. There are some descriptions about antifibrotic effects of Nitric-Oxide which are presumably mediated by cGMP in other organs
Data Source
Figure 1
Figure 2
AI summary
Use of s GC stimulators, sGC activators alone, or in combination with PDE5 inhibitors for the prevention and healing of Digital Ulcers which are concomitant to fibrotic diseases, such as systemic sclerosis and scleroderma.